Sturge-Weber syndrome results from a somatic mosaic activating variant in the GNAQ gene. This variant is not inherited from parents and does not run in families. The genetic change arises during early embryonic development and is therefore present in only a portion of the body's cells—those that developed from the affected cell lineage. Because the variant occurs post-fertilization in cells destined to form neural crest-derived tissues, it produces localized vascular malformations in the face, brain, and eyes rather than affecting all body systems uniformly. The proportion and tissue distribution of cells carrying the variant influences the extent and severity of the condition. The chance of having another affected sibling is extremely low, as the variant is not present in parental reproductive cells.

Diagnosis is established through the integration of clinical findings, neuroimaging, and ophthalmological evaluation. Brain MRI demonstrating leptomeningeal enhancement is a characteristic finding. Neuroimaging may also reveal cortical atrophy and parenchymal changes in affected regions. Electroencephalography supports assessment of seizure activity. Ophthalmological evaluation identifies glaucoma and related ocular features. Molecular testing for the somatic GNAQ variant in affected tissue can provide genetic confirmation, though sampling of an affected region is required given the mosaic nature of the variant.

No treatments are specifically FDA-approved for Sturge-Weber syndrome; management is multidisciplinary and focused on addressing each system's complications. Antiepileptic medications are used for seizure management. Low-dose aspirin therapy has been employed to reduce the frequency and severity of stroke-like episodes. Pulsed-dye laser treatment addresses the port-wine birthmark. Glaucoma is managed through regular ophthalmological monitoring and appropriate interventions, which may include medication or surgical procedures. Physical and occupational therapy support function in individuals with hemiparesis or other motor difficulties. Long-term management involves coordination among specialists in neurology, ophthalmology, dermatology, genetics, and rehabilitation medicine to detect and address evolving complications. Distinguishing ongoing surveillance—including regular neuroimaging and eye examinations—from interventions targeting active symptoms is central to comprehensive care planning.

Outcomes in Sturge-Weber syndrome vary considerably based on the extent of central nervous system involvement, the frequency of neurological events such as seizures and stroke-like episodes, and the degree of cognitive impact. Individuals with Type II presentation limited to facial involvement without CNS angiomatosis generally experience a more favorable course. Those with significant leptomeningeal involvement may experience progressive neurological deficits. The severity of epilepsy and the response of seizures to treatment are important determinants of functional outcome.

Active clinical research is ongoing in Sturge-Weber syndrome. A longitudinal neuroimaging study is examining brain changes over time in affected individuals (NCT04517565; Wayne State University; status: active, not recruiting; estimated completion June 2026). A separate study is investigating biomarkers and imaging approaches to gauge disease progression (NCT01425944; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; status: active, not recruiting; estimated completion February 2027). ClinicalTrials.gov maintains a current listing of research studies relevant to Sturge-Weber syndrome.